Cargando…
Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides
Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), is characterized by malignant CD4+ skin-homing T-cells that drive formation of cutaneous patches, plaques, and/or tumors. MF’s known immunogenicity makes it an ideal candidate for local immunotherapy. Recombinant human...
Autores principales: | Hu, Jamie Katy, Carlson, Kacie, Girardi, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
YJBM
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087069/ https://www.ncbi.nlm.nih.gov/pubmed/32226334 |
Ejemplares similares
-
CD8(+) mycosis fungoides palmaris et plantaris with peripheral blood involvement
por: Yumeen, Sara, et al.
Publicado: (2020) -
Real-world data on the effectiveness and safety of interferon-alpha-2a intralesional injection for the treatment of focally recalcitrant mycosis fungoides
por: Zhang, Shi-Yu, et al.
Publicado: (2020) -
Follow-up of patients with mycosis fungoides after interferon α2b treatment failure
por: Chmielowska, Ewa, et al.
Publicado: (2015) -
Ultra-Low-Dose Radiotherapy for Palliation of Mycosis Fungoides
por: Aral, İpek Pınar, et al.
Publicado: (2020) -
Efficacy of low-dose radiotherapy for refractory mycosis fungoides of the face
por: Masters, Adrianna Henson, et al.
Publicado: (2019)